Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation

Active, not recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

May 4, 2021

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2029

Conditions
Mitral Valve Regurgitation
Interventions
DEVICE

Tendyne™ Mitral Valve System

Transcatheter mitral valve implantation (TMVI) using the Tendyne™ Mitral Valve System , in which a bioprosthetic valve is implanted within the native mitral valve.

Trial Locations (36)

Unknown

Kepler University Hospital, Linz

UZ Gasthuisberg, Leuven

University Hospital Olomouc, Olomouc

IKEM Prague, Prague

Hospital AGEL Trinec-Podlesi, Třinec

Bordeaux University Hospital, Bordeaux

CHRU de Lille, Lille

Lyon University Hospital, Lyon

Rennes University Hospital, Rennes

Clinique Pasteur, Toulouse

Heart and Diabetes Center NRW, Bad Oeynhausen

German Heart Center Berlin, Berlin

University Hospital Bonn, Bonn

Universitätsclinic Cologne, Cologne

University Hospital Frankfurt, Frankfurt

University Heart Center Hamburg, Hamburg

Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel

Leipzig Heart Center, Leipzig

University Medical Center Mainz, Mainz

German Heart Center Munich, Munich

Ludwig-Maximilians-Universität (LMU) München / Campus Großhadern, München

Robert-Bosch Krankenhaus, Stuttgart

Shaare Zedek Jerusalem, Jerusalem

Sheba Medical Centre, Tel Aviv

Lancisi Cardiovascular Center - Politechnic University of Marcher, Ancona

AOU Civili Brescia, Brescia

Azienda Ospedaliero Universitaria Pisana, Pisa

MUMC+, Maastricht

Oslo University Hospital, Oslo

King Fahad Armed Forces, Jeddah

King Fahad Medical City, Riyadh

King Faisal Specialist Hospital & Research Center, Riyadh

Clinico San Carlos, Madrid

University Hospital Basel, Clinic for Cardiac Surgery, Basel

Insel Bern, Bern

Royal Brompton Hospital, London

Sponsors
All Listed Sponsors
lead

Abbott Medical Devices

INDUSTRY